(Reuters) -Drugmaker Pfizer posted a better than expected fourth quarter profit on Thursday, helped by cost cuts and a ...

Pfizer shares, which had risen Tuesday morning after improved demand for the Covid vaccine, dropped 2.3% after Kennedy's ...

A nasal vaccine for COVID-19—based on technology developed at Washington University in St. Louis—is poised to enter a phase 1 ...

Michigan's largest health system urges patients to seek nonemergency care at sites other than its ERs amid a surge in flu, ...

RSV, respiratory syncytial virus, usually peaks in December and January while infecting the nose, throat and lungs, usually ...

Fla., praised news that President Donald Trump will reinstate service members expelled for refusing to take the COVID-19 ...

Dr Sonali Mukherjee-Bose told a colleague there would be ‘no risk and good remuneration’ if they created the fake documents ...

Dr. Matthew Memoli, a National Institute of Allergy and Infectious Diseases researcher focused on flu and other respiratory ...

Trump's executive orders for the Pentagon will fulfill campaign promises that the Republican reiterated during last week's ...

Many nursing home residents are refusing COVID shots this winter, though flu vaccine penetration has remained strong historically.

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of ...